Cargando…
A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential
Interleukin-6 (IL-6), a pleiotropic cytokine that regulates immune responses and inflammatory reactions, plays a pivotal role in the development of rheumatoid arthritis (RA). Blockade of IL-6 signaling with the monoclonal antibody (mAb) represents an important advancement in RA treatment. Although t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808405/ https://www.ncbi.nlm.nih.gov/pubmed/35126375 http://dx.doi.org/10.3389/fimmu.2021.816646 |
_version_ | 1784643879878787072 |
---|---|
author | Liu, Xiaolei Li, Li Wang, Qian Jiang, Fengchao Zhang, Pei Guo, Fei Liu, Hongjun Huang, Jian |
author_facet | Liu, Xiaolei Li, Li Wang, Qian Jiang, Fengchao Zhang, Pei Guo, Fei Liu, Hongjun Huang, Jian |
author_sort | Liu, Xiaolei |
collection | PubMed |
description | Interleukin-6 (IL-6), a pleiotropic cytokine that regulates immune responses and inflammatory reactions, plays a pivotal role in the development of rheumatoid arthritis (RA). Blockade of IL-6 signaling with the monoclonal antibody (mAb) represents an important advancement in RA treatment. Although two IL-6 receptor antibodies are already available in the clinic, there is no mAb specifically targeting the human IL-6 to block IL-6 signaling for RA treatment. In this study, we have developed a novel humanized anti-IL-6 mAb HZ-0408b with potent binding and neutralizing activity to human IL-6. We demonstrated that HZ-0408b has a high species specificity and low cross-reactivity. Moreover, HZ-0408b showed a more potent inhibitory effect on IL-6 signaling than Siltuximab, an FDA-approved anti-IL-6 chimeric mAb. HZ-0408b is comparable to Olokizumab, a humanized mAb against IL-6 that is already in phase III studies. We observed that HZ-0408b is well tolerated at doses that can achieve therapeutic serum levels in cynomolgus monkey. Most importantly, we proved that HZ-0408b treatment significantly ameliorated joint swelling after the onset of arthritis and dramatically reduced plasma C-reactive protein (CRP) levels in a monkey collagen-induced arthritis (CIA) model. Collectively, our findings using non-human primates indicate that humanized anti-IL-6 mAb HZ-0408b has excellent safety and efficacy profiles for RA therapy. |
format | Online Article Text |
id | pubmed-8808405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88084052022-02-03 A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential Liu, Xiaolei Li, Li Wang, Qian Jiang, Fengchao Zhang, Pei Guo, Fei Liu, Hongjun Huang, Jian Front Immunol Immunology Interleukin-6 (IL-6), a pleiotropic cytokine that regulates immune responses and inflammatory reactions, plays a pivotal role in the development of rheumatoid arthritis (RA). Blockade of IL-6 signaling with the monoclonal antibody (mAb) represents an important advancement in RA treatment. Although two IL-6 receptor antibodies are already available in the clinic, there is no mAb specifically targeting the human IL-6 to block IL-6 signaling for RA treatment. In this study, we have developed a novel humanized anti-IL-6 mAb HZ-0408b with potent binding and neutralizing activity to human IL-6. We demonstrated that HZ-0408b has a high species specificity and low cross-reactivity. Moreover, HZ-0408b showed a more potent inhibitory effect on IL-6 signaling than Siltuximab, an FDA-approved anti-IL-6 chimeric mAb. HZ-0408b is comparable to Olokizumab, a humanized mAb against IL-6 that is already in phase III studies. We observed that HZ-0408b is well tolerated at doses that can achieve therapeutic serum levels in cynomolgus monkey. Most importantly, we proved that HZ-0408b treatment significantly ameliorated joint swelling after the onset of arthritis and dramatically reduced plasma C-reactive protein (CRP) levels in a monkey collagen-induced arthritis (CIA) model. Collectively, our findings using non-human primates indicate that humanized anti-IL-6 mAb HZ-0408b has excellent safety and efficacy profiles for RA therapy. Frontiers Media S.A. 2022-01-19 /pmc/articles/PMC8808405/ /pubmed/35126375 http://dx.doi.org/10.3389/fimmu.2021.816646 Text en Copyright © 2022 Liu, Li, Wang, Jiang, Zhang, Guo, Liu and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Liu, Xiaolei Li, Li Wang, Qian Jiang, Fengchao Zhang, Pei Guo, Fei Liu, Hongjun Huang, Jian A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential |
title | A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential |
title_full | A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential |
title_fullStr | A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential |
title_full_unstemmed | A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential |
title_short | A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential |
title_sort | novel humanized anti-interleukin-6 antibody hz0408b with anti-rheumatoid arthritis therapeutic potential |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808405/ https://www.ncbi.nlm.nih.gov/pubmed/35126375 http://dx.doi.org/10.3389/fimmu.2021.816646 |
work_keys_str_mv | AT liuxiaolei anovelhumanizedantiinterleukin6antibodyhz0408bwithantirheumatoidarthritistherapeuticpotential AT lili anovelhumanizedantiinterleukin6antibodyhz0408bwithantirheumatoidarthritistherapeuticpotential AT wangqian anovelhumanizedantiinterleukin6antibodyhz0408bwithantirheumatoidarthritistherapeuticpotential AT jiangfengchao anovelhumanizedantiinterleukin6antibodyhz0408bwithantirheumatoidarthritistherapeuticpotential AT zhangpei anovelhumanizedantiinterleukin6antibodyhz0408bwithantirheumatoidarthritistherapeuticpotential AT guofei anovelhumanizedantiinterleukin6antibodyhz0408bwithantirheumatoidarthritistherapeuticpotential AT liuhongjun anovelhumanizedantiinterleukin6antibodyhz0408bwithantirheumatoidarthritistherapeuticpotential AT huangjian anovelhumanizedantiinterleukin6antibodyhz0408bwithantirheumatoidarthritistherapeuticpotential AT liuxiaolei novelhumanizedantiinterleukin6antibodyhz0408bwithantirheumatoidarthritistherapeuticpotential AT lili novelhumanizedantiinterleukin6antibodyhz0408bwithantirheumatoidarthritistherapeuticpotential AT wangqian novelhumanizedantiinterleukin6antibodyhz0408bwithantirheumatoidarthritistherapeuticpotential AT jiangfengchao novelhumanizedantiinterleukin6antibodyhz0408bwithantirheumatoidarthritistherapeuticpotential AT zhangpei novelhumanizedantiinterleukin6antibodyhz0408bwithantirheumatoidarthritistherapeuticpotential AT guofei novelhumanizedantiinterleukin6antibodyhz0408bwithantirheumatoidarthritistherapeuticpotential AT liuhongjun novelhumanizedantiinterleukin6antibodyhz0408bwithantirheumatoidarthritistherapeuticpotential AT huangjian novelhumanizedantiinterleukin6antibodyhz0408bwithantirheumatoidarthritistherapeuticpotential |